271 related articles for article (PubMed ID: 25547910)
21. Recent progress in the development of protein-protein interaction inhibitors targeting androgen receptor-coactivator binding in prostate cancer.
Biron E; Bédard F
J Steroid Biochem Mol Biol; 2016 Jul; 161():36-44. PubMed ID: 26196120
[TBL] [Abstract][Full Text] [Related]
22. Regulation of Molecular Biomarkers Associated with the Progression of Prostate Cancer.
Martin-Caraballo M
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673756
[TBL] [Abstract][Full Text] [Related]
23. Growth factor and signaling pathways and their relevance to prostate cancer therapeutics.
Wozney JL; Antonarakis ES
Cancer Metastasis Rev; 2014 Sep; 33(2-3):581-94. PubMed ID: 24402967
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic targeting of SPINK1-positive prostate cancer.
Ateeq B; Tomlins SA; Laxman B; Asangani IA; Cao Q; Cao X; Li Y; Wang X; Feng FY; Pienta KJ; Varambally S; Chinnaiyan AM
Sci Transl Med; 2011 Mar; 3(72):72ra17. PubMed ID: 21368222
[TBL] [Abstract][Full Text] [Related]
25. Molecular alterations in prostate cancer and association with MRI features.
Lee D; Fontugne J; Gumpeni N; Park K; MacDonald TY; Robinson BD; Sboner A; Rubin MA; Mosquera JM; Barbieri CE
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):430-435. PubMed ID: 28762374
[TBL] [Abstract][Full Text] [Related]
26. Androgen receptors in early and castration resistant prostate cancer: friend or foe?
Pelekanou V; Notas G; Stathopoulos EN; Castanas E; Kampa M
Hormones (Athens); 2013; 12(2):224-35. PubMed ID: 23933691
[No Abstract] [Full Text] [Related]
27. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
[TBL] [Abstract][Full Text] [Related]
28. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
29. ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype.
Smith AM; Findlay VJ; Bandurraga SG; Kistner-Griffin E; Spruill LS; Liu A; Golshayan AR; Turner DP
Carcinogenesis; 2012 Mar; 33(3):572-80. PubMed ID: 22232738
[TBL] [Abstract][Full Text] [Related]
30. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N
Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.
Frank S; Nelson P; Vasioukhin V
F1000Res; 2018; 7():. PubMed ID: 30135717
[TBL] [Abstract][Full Text] [Related]
32. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Liu L; Dong X
PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
[TBL] [Abstract][Full Text] [Related]
33. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.
Bose R; Karthaus WR; Armenia J; Abida W; Iaquinta PJ; Zhang Z; Wongvipat J; Wasmuth EV; Shah N; Sullivan PS; Doran MG; Wang P; Patruno A; Zhao Y; ; Zheng D; Schultz N; Sawyers CL
Nature; 2017 Jun; 546(7660):671-675. PubMed ID: 28614298
[TBL] [Abstract][Full Text] [Related]
34. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells.
Chen T; Wang LH; Farrar WL
Cancer Res; 2000 Apr; 60(8):2132-5. PubMed ID: 10786674
[TBL] [Abstract][Full Text] [Related]
35. Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review).
Toren P; Zoubeidi A
Int J Oncol; 2014 Nov; 45(5):1793-801. PubMed ID: 25120209
[TBL] [Abstract][Full Text] [Related]
36. Targeting the relaxin hormonal pathway in prostate cancer.
Neschadim A; Summerlee AJ; Silvertown JD
Int J Cancer; 2015 Nov; 137(10):2287-95. PubMed ID: 25043063
[TBL] [Abstract][Full Text] [Related]
37. Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy.
Wu J; Yu E
Cancer Metastasis Rev; 2014 Sep; 33(2-3):607-17. PubMed ID: 24414227
[TBL] [Abstract][Full Text] [Related]
38. ETS fusion genes in prostate cancer.
Gasi Tandefelt D; Boormans J; Hermans K; Trapman J
Endocr Relat Cancer; 2014 Jun; 21(3):R143-52. PubMed ID: 24659477
[TBL] [Abstract][Full Text] [Related]
39. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer.
Burkhardt L; Fuchs S; Krohn A; Masser S; Mader M; Kluth M; Bachmann F; Huland H; Steuber T; Graefen M; Schlomm T; Minner S; Sauter G; Sirma H; Simon R
Cancer Res; 2013 May; 73(9):2795-805. PubMed ID: 23492366
[TBL] [Abstract][Full Text] [Related]
40. Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.
Wang L; Williamson SR; Zhang S; Huang J; Montironi R; Davison DD; Wang M; Yao JL; Lopez-Beltran A; Osunkoya AO; MacLennan GT; Baldridge LA; Du X; Cheng L
Mol Carcinog; 2015 Sep; 54(9):900-7. PubMed ID: 24777847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
